Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UPCOMING Rx-TO-OTC SWITCH REVIEWS PROVIDE NEEDED GOOD NEWS FOR DRUG STOCKS

This article was originally published in The Tan Sheet

Executive Summary

UPCOMING Rx-TO-OTC SWITCH REVIEWS PROVIDE NEEDED GOOD NEWS FOR DRUG STOCKS in the second quarter of 1994, contributing to gains made by Johnson & Johnson (up 13,6% on a 5-1/8-point gain to 42- 7/8) and SmithKline Beecham (up 12.5% on a 3-1/8-point increase to 28-1/8). J&J/Merck's Rx-to-OTC switch NDA for Pepcid (famotidine) is scheduled to be reviewed by FDA's Nonprescription Drugs and Gastrointestinal Drugs Advisory Committees on July 29 while SmithKline Beecham's switch application for Tagamet is set to be revisited by the committees on July 27 ("The Tan Sheet" June 27, p. 1).
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS083015

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel